Pathology, Biomarkers & Staging: Decoding Your Report

Your pathology report is the “blueprint” for your cancer care. It provides the essential data points your medical team uses to determine the most effective treatments for your specific situation. This guide will help you translate that complex document into actionable information.

Your Pathology Checklist

To fully understand your diagnosis and treatment options, ensure your report includes the following five critical pieces of information ^[1][2]:

• Subtype (Histotype): The specific type of cell (e.g., high-grade serous, clear cell).
• Grade: How abnormal the cells look (Grade 1 is slow-growing; Grade 3 is more aggressive) ^[3].
• Stage: How far the cancer has spread in the body ^[4].
• BRCA1/2 Status: Whether you have inherited or acquired mutations in these key genes ^[5].
• HRD Status: Whether the cancer has a specific DNA repair deficiency ^[6].

Understanding Staging (2014 FIGO System)

Staging describes the extent of the cancer. The FIGO system is the international standard for classifying ovarian, fallopian tube, and peritoneal cancers ^[4].

A Note on Timing: It is completely normal if your doctor cannot tell you your definitive stage right away. The official stage is often only confirmed after your surgery is complete and the pathologist has thoroughly examined all the removed tissues ^[4].

Stage I: Contained to the Ovaries or Fallopian Tubes

Stage I is often subdivided into Stage IC to reflect how the cancer was found or handled during surgery:

• IC1: A “surgical spill” occurred during the operation ^[7].
• IC2: The tumor surface had cancer on it, or the capsule (outer covering) broke open before surgery ^[7].
• IC3: Malignant cells were found in the fluid of your abdomen or “washings” taken during surgery ^[7].

Stage II: Spread within the Pelvis

Cancer has spread to nearby organs like the uterus or bladder, but is still within the pelvic region ^[4].

Stage III: Spread to the Abdomen or Lymph Nodes

This stage includes spread to the omentum (the fat pad in the abdomen) or to the lymph nodes ^[4]. Lymph node involvement is an important prognostic factor and may influence the intensity of your chemotherapy ^[3][1].

Stage IV: Distant Spread

• Stage IVA: Cancer cells are found in the fluid around the lungs ^[7].
• Stage IVB: Cancer has spread to distant organs like the liver or lungs, or to lymph nodes outside the abdomen (like those in the groin) ^[7].

Decoding Key Biomarkers

Biomarkers are measurable substances that help guide your treatment and monitor your progress.

• CA-125 & HE4: These are blood proteins. CA-125 is used to monitor how well treatment is working, while HE4 often provides higher specificity in distinguishing between benign and malignant masses ^[8][9]. The ROMA score combines both to assess the risk of malignancy ^[10].
• BRCA1/2: Mutations in these genes mean the cancer cells cannot repair DNA normally. This makes them particularly sensitive to certain modern therapies ^[5].
• Homologous Recombination Deficiency (HRD): This is a genomic state where the cancer can’t repair double-strand DNA breaks ^[6]. Patients with HRD-positive tumors often see significant benefit from a class of maintenance drugs called PARP inhibitors ^[11][12].

These factors—stage, grade, and biomarkers—directly dictate whether you will receive chemotherapy, targeted maintenance therapy, or a combination of both ^[11][13].